Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Karina Kapusta, Natalia Sizochenko, Micah L. Anderson, Wojciech Kolodziejczyk, Eugene O. Voronkov, Julia Saloni, Jerzy Leszczynski & Glake A. Hill. (2021) N-arylnaphthylamines as inhibitors of human immunodeficiency virus integrase - lens epithelium-derived growth factor interactions: theoretical studies. Journal of Biomolecular Structure and Dynamics 39:3, pages 867-880.
Read now
Read now
Lidija Kovač & Zdenko Časar. (2020) A literature review of the patent application publications on cabotegravir – an HIV integrase strand transfer inhibitor. Expert Opinion on Therapeutic Patents 30:3, pages 195-208.
Read now
Read now
Umesh Panwar & Sanjeev Kumar Singh. (2018) Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75). Journal of Biomolecular Structure and Dynamics 36:12, pages 3199-3217.
Read now
Read now
Xiqiang Cheng, Ping Gao, Lin Sun, Ye Tian, Peng Zhan & Xinyong Liu. (2017) Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. Expert Opinion on Therapeutic Patents 27:11, pages 1277-1286.
Read now
Read now
Thibault Mesplède, Peter K. Quashie, Veronica Zanichelli & Mark A. Wainberg. (2014) Integrase strand transfer inhibitors in the management of HIV-positive individuals. Annals of Medicine 46:3, pages 123-129.
Read now
Read now
Alessandra Fantauzzi, Ombretta Turriziani & Ivano Mezzaroma. (2013) Potential benefit of dolutegravir once daily: efficacy and safety. HIV/AIDS - Research and Palliative Care 5, pages 29-40.
Read now
Read now
Rik Schrijvers & Zeger Debyser. (2012) Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. Expert Opinion on Pharmacotherapy 13:13, pages 1969-1983.
Read now
Read now
Articles from other publishers (53)
Kongcheng Huang, Jianwu Lu, Xiaoxu Wang, Yinfei Shi, Kaimike Yang, Shun Yuan, Yinquan Wang, Han Sun, Yuebin Liu, Xun Sun & Taizhi Wu. (2023)
Improved Synthetic Process of Baloxavir Marboxil Intermediate 3-Benzyloxy-4-oxo-4
H
-pyran-2-carboxylic Acid
. Organic Process Research & Development 27:6, pages 1015-1026.
Crossref
Crossref
Shijie Wang, Xiuqing Song, Runzhi Sun, Hong Yan & Yeming Wang. (2023) Insight for the photochemical reaction of 4-aryl-4H-pyran: Experimental and theoretical studies. Tetrahedron 131, pages 133212.
Crossref
Crossref
Anil Kumar KotaMukthinuthalapati Mathrusri Annapurna. (2022) A new Stability-indicating UHPLC for the simultaneous determination of a combination of Anti-viral drugs: Dolutegravir sodium, Lamivudine and Tenofovir disoproxil fumarate. Research Journal of Pharmacy and Technology, pages 3823-3830.
Crossref
Crossref
Subhra Mandal, Shawnalyn W. Sunagawa, Pavan Kumar Prathipati, Michael Belshan, Annemarie Shibata & Christopher J. Destache. (2022) Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study. Nanomaterials 12:11, pages 1942.
Crossref
Crossref
Arif MERMER. (2021) Designing potential HIV-1 integrase inhibitors: An In silico approach. Turkish Journal of Analytical Chemistry 3:2, pages 45-53.
Crossref
Crossref
Vyshali Veerareddy, Sireesha Dodda & Kiran Gangarapu. (2021) Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form. European Journal of Mass Spectrometry 27:6, pages 249-255.
Crossref
Crossref
Yared Belete Belay, Eskinder Eshetu Ali, Karen Y. Chung, Gebremedhin Beedemariam Gebretekle & Beate Sander. (2021) Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia. PharmacoEconomics - Open 5:4, pages 655-664.
Crossref
Crossref
Nikunj S. PatelMr.Mr., Priyanka A. ShahDr.Dr., Rohit J. GajeraMr.Mr. & Hitesh D. PatelDr.Dr.. (2021) DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF RELATED SUBSTANCES PRESENT IN THE PHARMACEUTICAL DOSAGE FORM OF EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND DOLUTEGRAVIR. Towards Excellence, pages 627-644.
Crossref
Crossref
Nikunj S. PatelMr.Mr., Priyanka A. ShahDr.Dr., Rohit J. GajeraMr.Mr. & Hitesh D. PatelDr.Dr.. (2021) STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF EMTRICITABINE, DOLUTEGRAVIR AND TENOFOVIR ALAFENAMIDE IN THEIR COMBINED PHARMACEUTICAL DOSAGE FORM. Towards Excellence, pages 548-567.
Crossref
Crossref
Zaikuan J. YuEric P. MosherNamandjé N. Bumpus. (2021) Pharmacogenomics of Antiretroviral Drug Metabolism and Transport. Annual Review of Pharmacology and Toxicology 61:1, pages 565-585.
Crossref
Crossref
Zahra Hajimahdi, Rezvan Zabihollahi, Mohamad Reza Aghasadeghi & Afshin Zarghi. (2019) Design, Synthesis, Docking Studies and Biological Activities Novel 2,3- Diaryl-4-Quinazolinone Derivatives as Anti-HIV-1 Agents. Current HIV Research 17:3, pages 214-222.
Crossref
Crossref
Hajar Sirous, Afshin Fassihi, Simone Brogi, Giuseppe Campiani, Frauke Christ, Zeger Debyser, Sandra Gemma, Stefania Butini, Giulia Chemi, Alessandro Grillo, Rezvan Zabihollahi, Mohammad R. Aghasadeghi, Lotfollah Saghaie & Hamid R. Memarian. (2019) Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. Medicinal Chemistry 15:7, pages 755-770.
Crossref
Crossref
Hajar Sirous, Giulia Chemi, Sandra Gemma, Stefania Butini, Zeger Debyser, Frauke Christ, Lotfollah Saghaie, Simone Brogi, Afshin Fassihi, Giuseppe Campiani & Margherita Brindisi. (2019) Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. Frontiers in Chemistry 7.
Crossref
Crossref
Tamyres dos Santos Vieira, Isabela dos Santos Vieira, Matheus Bresser, Letícia Coutinho Lopes Moura & Marcos de Assis Moura. (2019) O papel do dolutegravir na terapia antiretroviral. HU Revista 44:3, pages 379-385.
Crossref
Crossref
Kaitlin Anstett, Bluma Brenner, Thibault Mesplède & Mark A. Wainberg. (2017) HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity. Journal of Virology 91:21.
Crossref
Crossref
John D. Schreier, Mark W. Embrey, Izzat T. Raheem, Guillaume Barbe, Louis-Charles Campeau, David Dubost, Jamie McCabe Dunn, Jay Grobler, Timothy J. Hartingh, Daria J. Hazuda, Daniel Klein, Michael D. Miller, Keith P. Moore, Natalie Nguyen, Natasa Pajkovic, David A. Powell, Vanessa Rada, John M. Sanders, John Sisko, Thomas G. Steele, John Wai, Abbas Walji, Min Xu & Paul J. Coleman. (2017) Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV. Bioorganic & Medicinal Chemistry Letters 27:9, pages 2038-2046.
Crossref
Crossref
Jose Ángel Fernández-Caballero, Natalia Chueca, Marta Álvarez, María Dolores Mérida, Josefa López, José Antonio Sánchez, David Vinuesa, María Ángeles Martínez, José Hernández & Federico García. (2016) Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure. BMC Infectious Diseases 16:1.
Crossref
Crossref
Jeffrey T. Kuethe, Guy R. Humphrey, Michel Journet, Zhihui Peng & Karla G. Childers. (2016) Asymmetric Synthesis of a Potent HIV-1 Integrase Inhibitor. The Journal of Organic Chemistry 81:21, pages 10256-10265.
Crossref
Crossref
Guan-Nan Liu, Rong-Hua Luo, Yu Zhou, Xing-Jie Zhang, Jian Li, Liu-Meng Yang, Yong-Tang Zheng & Hong Liu. (2016) Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives. Molecules 21:9, pages 1198.
Crossref
Crossref
Marina Sala, Antonia Spensiero, Francesca Esposito, Maria C. Scala, Ermelinda Vernieri, Alessia Bertamino, Michele Manfra, Alfonso Carotenuto, Paolo Grieco, Ettore Novellino, Marta Cadeddu, Enzo Tramontano, Dominique Schols, Pietro Campiglia & Isabel M. Gomez-Monterrey. (2016) Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase. Frontiers in Microbiology 7.
Crossref
Crossref
Nagasarapu Mallikarjuna Rao & Dannana Gowri Sankar. (2015) Development and validation of stability-indicating HPLC method for simeltaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form. Future Journal of Pharmaceutical Sciences 1:2, pages 73-77.
Crossref
Crossref
Tomas Doyle, David T. Dunn, Francesca Ceccherini-Silberstein, Carmen De Mendoza, Frederico Garcia, Erasmus Smit, Esther Fearnhill, Anne-Genevieve Marcelin, Javier Martinez-Picado, Rolf Kaiser & Anna Maria Geretti. (2015) Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. Journal of Antimicrobial Chemotherapy 70:11, pages 3080-3086.
Crossref
Crossref
Izzat T. Raheem, Abbas M. Walji, Daniel Klein, John M. Sanders, David A. Powell, Pravien Abeywickrema, Guillaume Barbe, Amrith Bennet, Sophie−Dorothee Clas, David Dubost, Mark Embrey, Jay Grobler, Michael J. Hafey, Timothy J. Hartingh, Daria J. Hazuda, Michael D. Miller, Keith P. Moore, Natasa Pajkovic, Sangita Patel, Vanessa Rada, Paul Rearden, John D. Schreier, John Sisko, Thomas G. Steele, Jean-François Truchon, John Wai, Min Xu & Paul J. Coleman. (2015) Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. Journal of Medicinal Chemistry 58:20, pages 8154-8165.
Crossref
Crossref
Kaitlin Anstett, Robert Fusco, Vincent Cutillas, Thibault Mesplède & Mark A. Wainberg. (2015) Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. Journal of Virology 89:20, pages 10482-10488.
Crossref
Crossref
Masako Nishizawa, Masakazu Matsuda, Junko Hattori, Teiichiro Shiino, Tetsuro Matano, Walid Heneine, Jeffrey A. Johnson & Wataru Sugiura. (2015) Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy. PLOS ONE 10:9, pages e0135941.
Crossref
Crossref
Giuliana Cuzzucoli Crucitti, Luca Pescatori, Antonella Messore, Valentina Noemi Madia, Giovanni Pupo, Francesco Saccoliti, Luigi Scipione, Silvano Tortorella, Francesco Saverio Di Leva, Sandro Cosconati, Ettore Novellino, Zeger Debyser, Frauke Christ, Roberta Costi & Roberto Di Santo. (2015) Discovery of N-aryl-naphthylamines as in vitro inhibitors of the interaction between HIV integrase and the cofactor LEDGF/p75. European Journal of Medicinal Chemistry 101, pages 288-294.
Crossref
Crossref
Thibault Mesplède & Mark Wainberg. (2015) Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses 7:7, pages 3703-3718.
Crossref
Crossref
Andrea Boesch, Valentino Cattori, Barbara Riond, Barbara Willi, Marina L. Meli, Katharina M. Rentsch, Margaret J. Hosie, Regina Hofmann-Lehmann & Hans Lutz. (2015) Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress™) on the course of progressive feline leukemia virus infection. Veterinary Microbiology 175:2-4, pages 167-178.
Crossref
Crossref
Abbas M. Walji, Rosa I. Sanchez, Sophie-Dorothee Clas, Rebecca Nofsinger, Manuel de Lera Ruiz, Jing Li, Amrithraj Bennet, Christopher John, David Jonathan Bennett, John M. Sanders, Christina N. Di Marco, Somang Hope Kim, Jaume Balsells, Scott S. Ceglia, Qun Dang, Kimberly Manser, Becky Nissley, John S. Wai, Michael Hafey, Junying Wang, Gene Chessen, Allen Templeton, John Higgins, Ronald Smith, Yunhui Wu, Jay Grobler & Paul J. Coleman. (2015) Discovery of MK-8970: An Acetal Carbonate Prodrug of Raltegravir with Enhanced Colonic Absorption. ChemMedChem 10:2, pages 245-252.
Crossref
Crossref
Pradipbhai D. Kalariya, Prinesh N. Patel, R. Srinivas & M. V. N. Kumar Talluri. (2015) Quality by design based development of a selective stability-indicating UPLC method of dolutegravir and characterization of its degradation products by UPLC-QTOF-MS/MS. New Journal of Chemistry 39:8, pages 6303-6314.
Crossref
Crossref
Melissa Wares, Thibault Mesplède, Peter K Quashie, Nathan Osman, Yingshan Han & Mark A Wainberg. (2014) The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:1.
Crossref
Crossref
M. Pollicita, M. Surdo, F. Di Santo, M. F. Cortese, L. Fabeni, V. Fedele, I. Malet, A.-G. Marcelin, V. Calvez, F. Ceccherini-Silberstein, C. F. Perno & V. Svicher. (2014) Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. Journal of Antimicrobial Chemotherapy 69:9, pages 2412-2419.
Crossref
Crossref
Vasu Nair, Maurice Okello, Sanjay Mishra, Jon Mirsalis, Kathleen O’Loughlin & Yu Zhong. (2014) Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor. Antiviral Research 108, pages 25-29.
Crossref
Crossref
Xue Zhi Zhao, Steven J. Smith, Mathieu Métifiot, Christophe Marchand, Paul L. Boyer, Yves Pommier, Stephen H. Hughes & Terrence R. BurkeJr.Jr.. (2014) 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1. Journal of Medicinal Chemistry 57:12, pages 5190-5202.
Crossref
Crossref
Mark Naccarato, Deborah Yoong, Charles la Porte & Ignatius Fong. (2013) Amiodarone and Concurrent Antiretroviral Therapy: A Case Report and Review of the Literature. Antiviral Therapy 19:4, pages 329-339.
Crossref
Crossref
Parul Patel, Ivy Song, Julie Borland, Shuguang Chen, Amanda Peppercorn, Toshihiro Wajima, Takeshi Funaki, Naomi Fujita, John Hughes & Stephen Piscitelli. (2013) Relative Bioavailability of a Paediatric Granule Formulation of the HIV Integrase Inhibitor Dolutegravir in Healthy Adult Subjects. Antiviral Therapy 19:3, pages 229-233.
Crossref
Crossref
Xue Zhi Zhao, Steven J. Smith, Mathieu Métifiot, Barry C. Johnson, Christophe Marchand, Yves Pommier, Stephen H. Hughes & Terrence R. BurkeJr.Jr.. (2014) Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants. Journal of Medicinal Chemistry 57:4, pages 1573-1582.
Crossref
Crossref
Roberto Di Santo. (2013) Inhibiting the HIV Integration Process: Past, Present, and the Future. Journal of Medicinal Chemistry 57:3, pages 539-566.
Crossref
Crossref
Chantelle Bennetto-Hood, Glenn Tabolt, Paul Savina & Edward P. Acosta. (2014) A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma. Journal of Chromatography B 945-946, pages 225-232.
Crossref
Crossref
Miłosz Parczewski. (2014) Stribild, as a novel option of integrase inhibitor based single tablet regimen for the treatment of HIV infection. HIV & AIDS Review 13:4, pages 101-105.
Crossref
Crossref
I.D. Ramsay, J.M. Lestner & C.I.S. Barker. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
503
550
.
Soundasse Munir, Sylvain Thierry, Frédéric Subra, Eric Deprez & Olivier Delelis. (2013) Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle. Retrovirology 10:1.
Crossref
Crossref
Thibault Mesplède, Peter K Quashie, Nathan Osman, Yingshan Han, Diane N Singhroy, Yolanda Lie, Christos J Petropoulos, Wei Huang & Mark A Wainberg. (2013) Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10:1.
Crossref
Crossref
Thibault Mesplède & Mark A. Wainberg. (2013) Integrase Strand Transfer Inhibitors in HIV Therapy. Infectious Diseases and Therapy 2:2, pages 83-93.
Crossref
Crossref
Sharon L. Karmon & Martin Markowitz. (2013) Next-Generation Integrase Inhibitors. Drugs 73:3, pages 213-228.
Crossref
Crossref
Peter K. Quashie, Thibault Mesplède & Mark A. Wainberg. (2013) Evolution of HIV integrase resistance mutations. Current Opinion in Infectious Diseases 26:1, pages 43-49.
Crossref
Crossref
Peter K. Quashie, Thibault Mesplède & Mark A. Wainberg. (2012) HIV Drug Resistance and the Advent of Integrase Inhibitors. Current Infectious Disease Reports 15:1, pages 85-100.
Crossref
Crossref
Miłosz Parczewski, Dorota Bander, Anna Urbańska & Anna Boroń-Kaczmarska. (2012) HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland. BMC Infectious Diseases 12:1.
Crossref
Crossref
Anna Maria Geretti, Daniele Armenia & Francesca Ceccherini-Silberstein. (2012) Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Current Opinion in Infectious Diseases 25:6, pages 677-686.
Crossref
Crossref
Xue Zhi Zhao, Kasthuraiah Maddali, Steven J. Smith, Mathieu Métifiot, Barry C. Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier & Terrence R. BurkeJr.Jr.. (2012) 6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters 22:24, pages 7309-7313.
Crossref
Crossref
Mark A Wainberg, Thibault Mesplède & Peter K Quashie. (2012) The development of novel HIV integrase inhibitors and the problem of drug resistance. Current Opinion in Virology 2:5, pages 656-662.
Crossref
Crossref
Thibault Mesplède, Peter K. Quashie & Mark A. Wainberg. (2012) Resistance to HIV integrase inhibitors. Current Opinion in HIV and AIDS 7:5, pages 401-408.
Crossref
Crossref
Mark A. Wainberg. (2012) The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica 2012, pages 1-28.
Crossref
Crossref